Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial Stats
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT07441837
Phase 2 Study of Terbium 161 PSMA in Lutetium-177 PSMA Naive mCRPC Patients
Overview
In this study it is aimed to analyze the efficacy and safety of Tb-161 PSMA I&T in the 7.4 GBq activity in a large patient group of Lu-177 PSMA naïve mCRPC patients. 3 cycles of Tb-161 PSMA will be administered with 6 weeks periods.
Sponsor
Ankara University
Phase
Phase 2
Contacts
Cigdem Soydal (Professor)
csoydal@yahoo.com
905333137701
ClinicalTrials.gov
NCT07441837Drug / Compound
Tb-161 PSMA I&T
Isotope(s):
TERBIUM-161
Radioisotope: Tb-161
Theranostic Role: Therapeutic Agent & SPECT Imaging
T1/2 (Half-Life): 6.9 Days
Decay Mode: BETA, GAMMA
Energy: Beta: Avg 154 keV Gamma: 49 keV (17%), 75 keV (10%)
Range: 0.5-30 micrometers
Decay Daughters: Dy161 (Stable)
Status: Clinical Trials Only
Target(s):
- PSMA
Ligand Class: Small Molecules
Chelator: DOTAGA
Share your feedback
Help us improve your experience